PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 65 | 4 | 29–37
Article title

Aktywność przeciwgrzybicza fl ukonazolu wobec klinicznych szczepów Candida albicans oraz innych Candida spp. – przegląd badań in vitro przeprowadzonych w różnych ośrodkach medycznych

Content
Title variants
EN
The antifungal activity of fl uconazole against clinical Candida albicans strains and other Candida spp. – the review of the research in vitro carried out in various medical centres
Languages of publication
PL
Abstracts
EN
Candida albicans species is the most common yeast isolated from the candidiasis, however the number of fungal infections caused by non-albicans Candida (Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida krusei) has increased in recent years. Fluconazole is an eff ective and well tolerated the antifungal azole drug with parenteral and oral forms. This agent directed to 14-􀄮-demethylase lanosterol (the product of the ERG11 gene) – the enzyme important in the biosynthesis of ergosterol – the major constituent of fungal membranes. Antifungal drug resistance is associated with the molecular mechanisms, especially with the point mutations of the ERG11 gene and the expression of genes CDR1, CDR2, MDR1 encoding so called effl ux-pumps, the system of transport fl uconazole across the plasma membrane. The aim of this study was the review of the research in various medical centres and the evaluation of the susceptibility of Candida albicans strains and other Candida spp. to fluconazole. These strains obtained from the clinical samples of the patients hospitalized. The fluconazole activity against the yeasts isolates was evaluated in vitro using the reference methods according by the CLSI, predominantly by the broth dilution methods with the determination the minimum inhibitory concentration MIC. Here are the conclusions obtained on the basis of the presented research: 1. The isolates of Candida spp. showed diff erent levels of susceptibility to fluconazole. 2. It’s important to determine the susceptibility of Candida spp. to fluconazole before beginning of treatment to improve the treatment outcome.
PL
Candida albicans to najczęściej izolowany gatunek w przypadku kandydoz, jednakże liczba infekcji grzybiczych z udziałem non-albicans Candida (Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida krusei) w ostatnich latach wyraźnie wzrosła. Flukonazol jest skutecznym i dobrze tolerowanym lekiem przeciwgrzybiczym – azolem, stosowanym w formie parenteralnej lub doustnej. Lek ten celuje w 14-􀄮-demetylazę lanosterolu (produkt genu ERG11), enzym istotny w biosyntezie ergosterolu będącego głównym składnikiem błony komórkowej grzyba. Oporność na flukonazol jest związana z istnieniem molekularnych mechanizmów, szczególnie z punktowymi mutacjami w genie ERG11 i ekspresją genów CDR1,CDR2, MDR1 kodujących tzw. effl ux-pumps, tj. system transportu niezbędny do wyrzutu fl ukonazolu przez błonę komórkową. Celem niniejszej pracy było dokonanie przeglądu badań z różnych ośrodków medycznych, dotyczących oceny wrażliwości na fl ukonazol szczepów Candida albicans i innych Candida spp. wyizolowanych z materiałów klinicznych pobranych od hospitalizowanych pacjentów. Aktywność flukonazolu wobec izolatów drożdżaków była oceniana referencyjnymi metodami zgodnymi z zaleceniami CLSI, z przewagą metod rozcieńczeniowych, pozwalających na określenie minimalnego stężenia hamującego MIC. Na podstawie wyników analizowanych badań można sformułować następujące wnioski: 1. Kliniczne szczepy Candida spp. cechują się zróżnicowanym poziomem wrażliwości na flukonazol. 2. Istotne wydaje się oznaczanie wrażliwości Candida spp. na flukonazol przed rozpoczęciem leczenia, w celu uzyskania pozytywnych wyników terapii.
Keywords
Discipline
Year
Volume
65
Issue
4
Pages
29–37
Physical description
References
  • 1. Traboulsi R.S., Mukherjee P.K., Ghannoum M.A. In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV–infected patients. Int. J. Antimicrob. Agents. 2008; 31: 272–276.
  • 2. Cernicka J., Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int. J. Antimicrob. Agents. 2006; 27: 403–408.
  • 3. Fleck R., Dietz A., Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J. Antimicrob. Chemother. 2007; 59: 767–771.
  • 4. Arechavala A.I., Bianchi M.H., Robles A.M., Santiso G., Negroni R. Identifi cation and susceptibility against fl uconazole and albaconazole of 100 yeasts’strains isolated from vaginal discharge. Rev. Iberoam. Micol. 2007; 24: 305–308.
  • 5. Xu Y., Chen L., Li C. Susceptibility of clinical isolates of Candida species to fl uconazole and detection of Candida albicans ERG11 mutations. J. Antimicrob. Chemother. 2008; 61: 798–804.
  • 6. Jafari-nodoushan A.A., Kazemi A., Mirzaii F., Dehghani M. Fluconazole susceptibility profi le of Candida isolates recovered from patients specimens admitted to Yazd Central Laboratory. IJPR 2008; 7: 69–75.
  • 7. Shahum A., Liskova A., Kalavsky E., Krcmery V. Voriconazole resistant Candida spp. and Saccharomyces spp. isolates from oropharyngeal candidiasis from Cambodian children with AIDS not pretreated with azoles. Scand. J. Infect. Dis. 2007; 39: 286–287.
  • 8. Yang Y.L., Ho Y.A., Cheng H.H., Ho M., Lo H.J. Susceptibilites of Candida species to amphotericin B and fluconazole: The emergence of fl uconazole resistance in Candida tropicalis. Infect. Control. Hosp. Epidemiol. 2004; 25: 60–64.
  • 9. Macura A.B., Skóra M. Wrażliwość grzybów wyizolowanych z pochwy na leki przeciwgrzybicze. Mikol. Lek. 2009; 16: 206–209.
  • 10. Fluconazolum (Flukonazol). [W:] Farmakopea Polska VIII. Warszawa: Polskie Towarzystwo Farmaceutyczne; 2008: t. II, str. 1763.
  • 11. Klepser M.E., Pharm D. Antifungal resistance among Candida species. Pharmacotherap. 2001; 21: 124S–132S.
  • 12. Baran E., Hryncewicz-Gwóźdź A., Plomer-Niezgoda E., Czarnecka A., Maj J., Cisło M. Ocena skuteczności leczenia grzybicy paznokci fl ukonazolem (Fluconazole firmy Polfarmex) w dawce 300 mg raz w tygodniu – wyniki pierwszego etapu badań. Mikol. Lek. 2006; 13: 207–210.
  • 13. Pappas P.G., Kauff man C.A., Andes D. i wsp. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009; 48; 503–535.
  • 14. Corvó R., Amichetti M., Ascarelli A. i wsp. Effects of fl uconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a doublebling placebo-controlled trial. Eur. J. Cancer Care 2008; 17: 270–277.
  • 15. Skrodenieně E., Dambrauskieně A., Vitkauskieně A. Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 2006; 42: 294–299.
  • 16. Gualco L., Debbia E.A., Bandettini R. i wsp. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int. J. Antimicrob. Agents. 2007; 29: 179–184.
  • 17. Negri M., Henriques M., Svidzinski T.I., Paula C.R., Oliveira R. Correlation between Etest, disk diff usion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization. J. Clin. Lab. Anal. 2009; 23: 324–330.
  • 18. Chunchanur S.K., Nadgir S.D., Halesh L.H., Patil B.S., Kausar Y., Chandrasekhar M.R. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodefi ciency virus-infected patients. Indian J. Pathol. Microbiol. 2009; 52: 501–504.
  • 19. Wang J.L., Chang S.C., Hsuch P.R., Chen Y.C. Species distribution and fl uconazole susceptibility of Candida clinical isolates in a medical center in 2002. J. Microbiol. Immunol. Infect. 2004; 37: 236–241.
  • 20. Vazquez J.A., Arganoza M.T., Boikov D., Vaishampayan J.K., Akins R.A. In vitro susceptibilities of Candida and Aspergillus species to Melaleuca alternifolia (tea tree) oil. Rev. Iberoam. Micol. 2000; 17: 60–63.
  • 21. Bagg J., Jackson M.S., Sweeney M.P., Ramage G., Davies A.N. Susceptibility to Melaleuca alternifolia (tea tree) oil of yeasts isolated from the mouths of patients with advanced cancer. Oral Oncol. 2006; 42: 487–492.
  • 22. Mondello F., De Bernardis F., Girolamo A., Salvatore G., Cassone A. In vitro and in vivo activity of tea tree oil against azolesusceptible and -resistant human pathogenic yeasts. J. Antimicrob. Chemother. 2003; 51: 1223–1229.
  • 23. Passos X.S., Costa C.R., Araújo C.R. i wsp. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia. 2007; 163: 145–151.
  • 24. Nawrot U., Nowicka J., Juszczak K., Gusin B. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases. Mycoses 2005; 48: 385–390.
  • 25. Dynowska M., Ejdys E., Kisicka I. Susceptibility to antifungal agents of yeastslike fungi and yeasts isolated from people with multifocal infections. Mikol. Lek. 2004; 11: 15–19.
  • 26. Mondello F., De Bernardis F., Girolamo A., Cassone A., Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Chel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect. Dis. 2006; 6: 158.
  • 27. Antibiotics for research applications. Antifungals. BioFiles–Life Science. 2009; 4(3): 10. URL: http://www.sigma.aldrichcom/ life-science/learning-center/biofi les. html.
  • 28. Kamai Y., Maebashi K., Kudoh M. i wsp. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a japanese patient with chronic mucocutaneous candidiasis. Microbiol. Immunol. 2004; 48: 937–943.
  • 29. Goldman G.H., da Silva Ferreira M.E., dos Reis Marques E. i wsp. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn. Microbiol. Infect. Dis. 2004; 50: 25–32.
  • 30. Angiolella L., Stringaro A.R., De Bernardis F. i wsp. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob. Agents Chemother. 2008; 52: 927–936.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-21fee150-3ca5-41d6-ac4a-212b06370426
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.